Sanofi-Aventis is teaming up with CureDM in a global licensing agreement worth as much as $335 million for diabetes drug Pancreate. The experimental compound is being developed as a "regenerative treatment" that could normalize insulin production and the function of other pancreatic hormones in Type 1 or Type 2 diabetics.

Full Story:

Related Summaries